BioSpace News Archive

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, has scheduled the release of its 2021 second quarter financial results for Friday, July 30, 2021 before the market opens

Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF) (“Bioasis”) and Oxyrane UK Ltd. (“Oxyrane”) are pleased to announce the initiation of a research collaboration.

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced dose administration for the first patient in the Phase 1, multicenter, open-label, first-in-human study of DCC-3116.

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), today announced that Chief Executive Officer Jonathan P. Mow will participate in a fireside chat during the upcoming William Blair Biotech Focus Conference 2021 taking place virtually on Thursday, July 15, 2021 at 1:00 pm – 1:45 pm EDT.

GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, announced the results of the voting by shareholders at the Combined Shareholders Meeting which took place on June 30, 2021 behind closed doors at the Company’s headquarters.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its second-quarter 2021 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Thursday, July 29.

McKesson Corporation (NYSE: MCK) will release its first quarter fiscal 2022 financial results after market close on Wednesday, August 4, 2021.

Protagonist Therapeutics, Inc. reported that on June 30, 2021, it issued an inducement award to Patrick Smith, the Company’s recently hired Vice President, Quality Assurance, in accordance with the terms of Mr. Smith’s employment offer letter.

CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced results from the final analysis of its 40,000 subject international pivotal Phase 2b/3 study (the HERALD study) of the first-generation COVID-19 vaccine candidate, CVnCoV.

Helix BioPharma Corp. (TSX:HBP) (‘Helix’ or the ‘Company’), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Heman Chao has notified the Board of Directors of the Company of his intention to step down from the position of Chief Executive Officer (“CEO”), Chief Scientific Officer (“CSO”) and member of the Board, effective September 1, 2021